FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Trading Up 3.3 %

FibroGen stock traded up $0.01 during midday trading on Wednesday, hitting $0.32. The stock had a trading volume of 943,413 shares, compared to its average volume of 1,271,437. The stock has a market cap of $32.43 million, a P/E ratio of -0.19 and a beta of 0.72. FibroGen has a 12 month low of $0.29 and a 12 month high of $2.93. The business has a fifty day moving average price of $0.37 and a 200 day moving average price of $0.74.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same quarter in the previous year, the firm earned ($0.65) earnings per share. On average, equities analysts anticipate that FibroGen will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Alpine Global Management LLC acquired a new position in FibroGen in the first quarter valued at approximately $25,000. Delap Wealth Advisory LLC acquired a new position in FibroGen in the first quarter valued at approximately $27,000. Acadian Asset Management LLC boosted its stake in FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock valued at $5,883,000 after acquiring an additional 34,937 shares during the period. Sei Investments Co. boosted its position in shares of FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the period. Finally, Point72 DIFC Ltd boosted its position in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.